Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.95−0.10 (-9.87%)
Close on Nov 16, 2026Market cap $26.27MP/E –Yield –
Inmune Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Inmune Bio's profit margin for the twelve months ending Dec 31, 2025 was -91866.0%. For fiscal 2025 it was -91866.0%, against -300585.7% the year before. The highest annual figure on record is -7299.2% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -91866.0% | +208719.7 |
| FY2024 | Dec 31, 2024 | -300585.7% | −281225.7 |
| FY2023 | Dec 31, 2023 | -19360.0% | −12060.8 |
| FY2022 | Dec 31, 2022 | -7299.2% | +9463.2 |
| FY2021 | Dec 31, 2021 | -16762.4% | +93228.5 |
| FY2020 | Dec 31, 2020 | -109990.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -19478.0% | −5345.4 |
| Q1 FY2024 | Mar 31, 2024 | -78750.0% | −61550.0 |
| Q4 FY2023 | Dec 31, 2023 | -30028.6% | −24015.2 |
| Q3 FY2023 | Sep 30, 2023 | -19914.0% | −12031.3 |
| Q2 FY2023 | Jun 30, 2023 | -14132.6% | +28604.9 |
| Q1 FY2023 | Mar 31, 2023 | -17200.0% | −12965.0 |
| Q4 FY2022 | Dec 31, 2022 | -6013.4% | −80.3 |
| Q3 FY2022 | Sep 30, 2022 | -7882.7% | +59674.5 |
| Q2 FY2022 | Jun 30, 2022 | -42737.5% | +71162.5 |
| Q1 FY2022 | Mar 31, 2022 | -4235.0% | – |
| Q4 FY2021 | Dec 31, 2021 | -5933.1% | – |
| Q3 FY2021 | Sep 30, 2021 | -67557.1% | – |
| Q1 FY2021 | Mar 31, 2021 | -113900.0% | – |
See a number that looks wrong?